Eprex*1sir 10000ui 1ml (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
18 | 脊髄小脳変性症(多系統萎縮症を除く。) | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2011-006156-37-IT (EUCTR) | 10/07/2012 | 26/07/2012 | Erythropoieitn in Friedreich Ataxia | A double-blind, randomized, placebo-controlled, clinical trial to test the efficacy of Epoetin alfa on physical performance of Friedreich Ataxia patients. - FRIEMAX | FRIEDREICH ATAXIA MedDRA version: 14.1;Level: PT;Classification code 10008025;Term: Cerebellar ataxia;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: EPREX*1SIR 40000UI/ML 1ML INN or Proposed INN: EPOETIN ALFA Trade Name: EPREX*1SIR 10000UI 1ML INN or Proposed INN: EPOETIN ALFA Trade Name: BINOCRIT*1SIR 40000UI/1ML INN or Proposed INN: EPOETIN ALFA | UNIVERSITA' DEGLI STUDI DI NAPOLI FEDERICO II | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | Italy |